Earnings look ahead – Ashtead, Inmarsat, Legal & General

A look at UK company earnings next week.

City of London skyline
Source: Bloomberg

Ashtead (full-year earnings 7 March)

Ashtead seems ideally placed to benefit from Donald Trump’s stimulus programme in the US, even if we still have precious few details on the actual stimulus. Nonetheless, the firm’s big US operations have already fired up investor enthusiasm, with the shares surging since the election. The shares have delivered an increase in earnings in each of the last five years, while its strong record of dividends is matched by a dividend coverage ratio of four times earnings. Watch for further comment on the potential opportunities offered in the US as a consequence of the Trump stimulus.

The shares have barely stopped since the election, reaching a new all-time high at the beginning of March. We may see some profit-taking following the results, but so long as the price doesn’t breach £14 it seems likely Ashtead will remain an investor favourite. Some near-term support may be found at the 50-day simple moving average (SMA), currently £16.30.

Inmarsat (full-year earnings 8 March)

Inmarsat’s future depends either on a takeover or success with its in-flight WiFi technology. The firm has been identified as a possible target for EchoStar, a major player in the satellite market, while its push into in-flight WiFi could yield great success, with IAG and Lufthansa both potential customers. A 4,9% year-on-year fall in revenue from the key maritime segment has put investors on watch for further problems, while the ostensibly attractive yield of around 6% is diminished by the fact earnings may not cover the payout this year. In addition, it still carries around $1.9 billion in net debt that needs clearing. The firm will need to spin a good tale on the coming year if the shares are not to suffer.

At the beginning of 2016 the shares were over the £11 mark. Since then the downtrend has been relentless; rallies have been furiously sold, with the latest push to £7.20 bringing out more bears. If the weekly pivot at £6.74 is lost then £6.06 and £5.90 come into play. 

Legal & General (full-year earnings 8 March)

Legal & General’s heavy UK focus made Brexit a particularly tumultuous event. However, the shares have recovered since the vote, with the steady performance of the UK housing market helping to reassure investors. Overall, the current valuation of around 14 times earnings does not look excessive, especially given the excellent dividend yield of 6%.

The share price has now pushed above its early January high of 252p, with 259p and then 271p the next targets. However, the rally also looks overstretched, so a pullback is eminently possible. However, so long as the price does not fall below the February low of 231p the uptrend remains in place.

IGA, may distribute information/research produced by its respective foreign marketing partners within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.

This information/research prepared by IGA or IGA Group is intended for general circulation. It does not take into account the specific investment objectives, financial situation or particular needs of any particular person. You should take into account your specific investment objectives, financial situation or particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. In addition to the disclaimer above, the information does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. Any views and opinions expressed may be changed without an update.

See important Research Disclaimer.